Liquidia Corp LQDA
Liquidia Corp (Nasdaq: LQDA) is a respiratory drug developer. Its lead program, L606 (liposomal treprostinil, inhaled via next-generation nebulizer), is in Phase 3 for pulmonary hypertension associated with interstitial lung disease (PH-ILD); also PAH (open-label). Its next catalyst on record is YUTREPIA: RE-WARM Phase 2a dose-finding study (~75 patients) expected to begin October 2026, primary completion targeted February 2027. (October 2026).
Upcoming catalysts
- October 2026YUTREPIA — RE-WARM Phase 2a dose-finding study (~75 patients) expected to begin October 2026, primary completion targeted February 2027.
The study is expected to begin in October 2026, with primary completion targeted for February 2027.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| YUTREPIA (treprostinil inhalation powder) | PAH and PH-ILD (approved May 2025); planned studies in PH-COPD, IPF, PPF, SSc-RP | device-combination | Approved |
| L606 pivotal study | PH-ILD | device-combination | Phase 3 |
| L606 open-label study (US) | PAH and PH-ILD | device-combination | Phase 2 |
| YUTREPIA new-indication studies | PH-COPD, IPF, PPF, SSc-RP | device-combination | Pre-clinical |
Recent results and decisions
- Oct 13, 2026submitted Liquidia submitted supplement to FDA to remove PH-ILD indication from YUTREPIA label as part of litigation settlement with United Therapeutics.
Liquidia has submitted a supplement to remove the PH-ILD indication from YUTREPIA's label and no longer promotes it for PH-ILD.
Filing - Oct 13, 2026discontinued Liquidia will terminate PH-ILD cohorts of the ASCENT trial and cease publishing new data from these cohorts until after expiration of the '327 Patent.
Liquidia also shall terminate cohorts of the ASCENT trial that are studying PH-ILD as promptly as practicable, cease and desist from publishing any new data, and cease and desist disseminating already published data, from cohorts of the ASCENT trial that are studying PH-ILD.
Filing - Oct 13, 2026n/a Liquidia entered into a global settlement agreement with United Therapeutics to resolve all pending litigation for a net payment of $380.7 million over multiple installments.
Liquidia to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to resolve antitrust litigation against United Therapeutics.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.